These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6189438)

  • 1. Immediate-release and sustained-release procainamide: bioavailability at steady state in cardiac patients.
    Vlasses PH; Rocci ML; Porrini KA; Greenspon AJ; Ferguson RK
    Ann Intern Med; 1983 May; 98(5 Pt 1):613-4. PubMed ID: 6189438
    [No Abstract]   [Full Text] [Related]  

  • 2. Dosage, plasms concentration and antiarrhythmic effect of procainamide in sustained-release tablets.
    Arstila M; Katila M; Sundquist H; Anttila M; Pere E; Tikkanen R
    Acta Med Scand; 1974 Mar; 195(3):217-22. PubMed ID: 4595254
    [No Abstract]   [Full Text] [Related]  

  • 3. [Serum concentrations of procainamide during treatment with ordinary and sustained-release tablets].
    Henningsen P; Laursen HB; Christiansen BD; Moller J
    Ugeskr Laeger; 1976 Sep; 138(40):2433-7. PubMed ID: 968997
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic comparisons of twice daily and four times daily formulations of procainamide in patients with frequent ventricular premature depolarization.
    Yang BB; Abel RB; Uprichard AC; Smithers JA; Forgue ST
    J Clin Pharmacol; 1996 Jul; 36(7):623-33. PubMed ID: 8844445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case.
    Kroboth PD; Mitchum K; Puschett JB
    Am J Kidney Dis; 1984 Jul; 4(1):78-9. PubMed ID: 6204527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procainamide acetylation and disposition in dialysis patients.
    Nattel S; Ogilvie RI; Kreeft J; Sitar DS; Graham DN; Rangno RE; Dufresne LR; Barre PE
    Clin Invest Med; 1979; 2(1):5-11. PubMed ID: 509808
    [No Abstract]   [Full Text] [Related]  

  • 7. [Oral administration of procainamide for ventricular arrhythmia. Plasma concentrations during use of tablets(Pronestyl) and a slow-release preparation (Porcainamide Durettes)].
    Bliddal J
    Ugeskr Laeger; 1976 Sep; 138(40):2425-33. PubMed ID: 968996
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma levels of procaine amide after administration of conventional and sustained-release tablets.
    Karlsson E
    Eur J Clin Pharmacol; 1973 Dec; 6(4):245-50. PubMed ID: 4591151
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias.
    Hilleman DE; Patterson AJ; Mohiuddin SM; Ortmeier BG; Destache CJ
    Drug Intell Clin Pharm; 1988; 22(7-8):554-8. PubMed ID: 2458219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Food-induced gastric retention and absorption of sustained-release procainamide.
    Rocci ML; Mojaverian P; Davis RJ; Ferguson RK; Vlasses PH
    Clin Pharmacol Ther; 1987 Jul; 42(1):45-9. PubMed ID: 2439252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new sustained-release tablet formulation of procainamide.
    Fremstad D; Dahl S; Jacobsen S; Lunde PK; Nådland KJ; Marthinsen AA; Waaler T; Landmark KH
    Eur J Clin Pharmacol; 1973 Dec; 6(4):251-5. PubMed ID: 4591152
    [No Abstract]   [Full Text] [Related]  

  • 12. Simultaneous determination of procainamide and N-acetylprocainamide in serum by gas chromatography with nitrogen-selective detection.
    Yamaji A; Kataoka K; Oishi M; Kanamori N; Hiraoka E; Mishima M
    J Chromatogr; 1987 Mar; 415(1):143-7. PubMed ID: 2438294
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical pharmacology of procainamide and its active metabolite -N-acetylprocainamide].
    Matusewicz W; Orszulak DE
    Przegl Lek; 1984; 41(5):379-83. PubMed ID: 6206523
    [No Abstract]   [Full Text] [Related]  

  • 14. [Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation].
    Pirovino M; Karlaganis G; Galeazzi RL
    Schweiz Med Wochenschr; 1980 Sep; 110(39):1415-9. PubMed ID: 6169144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of age, gender, and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets.
    Koup JR; Abel RB; Smithers JA; Eldon MA; de Vries TM
    Ther Drug Monit; 1998 Feb; 20(1):73-7. PubMed ID: 9485559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, plasma concentrations and adverse effects of a new sustained release procainamide preparation.
    Giardina EG; Fenster PE; Bigger JT; Mayersohn M; Perrier D; Marcus FI
    Am J Cardiol; 1980 Nov; 46(5):855-62. PubMed ID: 6159783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiences on a sustained-release procainamide preparation.
    Ruosteenoja R; Torsti P; Sothmann A
    Curr Ther Res Clin Exp; 1973 Oct; 15(10):707-12. PubMed ID: 4201315
    [No Abstract]   [Full Text] [Related]  

  • 18. Absorption kinetics of procainamide in humans.
    Manion CV; Lalka D; Baer DT; Meyer MB
    J Pharm Sci; 1977 Jul; 66(7):981-4. PubMed ID: 886461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a sustained release procainamide preparation.
    Flanagan AD
    Angiology; 1982 Feb; 33(2):71-7. PubMed ID: 7039427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of the acetylation phenotype and the therapeutic effect of procainamide.
    Schröder P; Klitgaard NA; Simonsen E
    Eur J Clin Pharmacol; 1979 Feb; 15(1):63-8. PubMed ID: 84761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.